Research Paper Volume 13, Issue 2 pp 2436—2458
FX5 as a non-steroidal GR antagonist improved glucose homeostasis in type 2 diabetic mice via GR/HNF4α/miR-122-5p pathway
Figure 7. A proposed model describing the regulation of FX5 against gluconeogenesis and glucose homeostasis. FX5 suppressed gluconeogenetic genes G6Pase and PEPCK, and improved hyperglycemia in T2DM mice by targeting GR and involving GR/HHNF4α and GR/HNF4α/miR122-5p pathways.